OneStep ELISA Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Homo sapiens (Human) Protein, Antibody, Assaykit, Service

CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1

  • UOM
    1. 48T
    2. 96T
  • FOB US$ 419.00 US$ 598.00
  • Quantity
Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • OneStep ELISA Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Packages (Simulation)
  • OneStep ELISA Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-96 87
EDTA plasma(n=5) 79-94 87
heparin plasma(n=5) 94-101 97

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 89-97% 96-103% 89-98% 92-101%
EDTA plasma(n=5) 96-103% 97-105% 79-90% 79-104%
heparin plasma(n=5) 90-97% 78-93% 95-103% 80-96%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well, then add 50µL prepared Detection Reagent A to each well. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
5. Add 50µL Stop Solution. Read at 450nm immediately.

OneStep ELISA Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)

Test principle

The test principle applied in this kit is Sandwich enzyme immunoassay. The microplate provided in this kit has been pre-coated with an antibody specific to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Standards or samples are then added to the appropriate microplate wells with a HRP-conjugated antibody specific to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). After TMB substrate solution is added, only those wells that contain Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Citations

  • Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathwayPubMed: 23398358
  • Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture studyPubMed: 26689470
  • Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture studyPubmed:26689470
  • A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells.pubmed:27925188
  • The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic10.1093/rb/rbx028
  • VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these …Pubmed:29985074
  • Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgarisPubmed: 32043381
  • Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells33523322
  • Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy34324118
  • Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneysPubmed:35643467

Recommend products